M
Maat Pharma SA
PAR:MAAT
Maat Pharma SA
PAR:MAAT
Price:
5.68
EUR
Market Closed
Market Cap:
€106.9m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
M
|
Maat Pharma SA
PAR:MAAT
|
FR |
|
Brookfield Renewable Partners LP
NYSE:BEP
|
BM |
|
Gesco AG
XETRA:GSC1
|
DE |
|
Media Nusantara Citra Tbk PT
IDX:MNCN
|
ID |
|
Invinity Energy Systems PLC
OTC:IESVF
|
JE |
|
P
|
Petrovietnam Transportation Corp
VN:PVT
|
VN |
|
Nippecraft Ltd
SGX:N32
|
SG |
|
Anyang Iron and Steel Co Ltd
SSE:600569
|
CN |
|
Sukhjit Starch and Chemicals Ltd
BSE:524542
|
IN |
|
B
|
Belluscura PLC
LSE:BELL
|
UK |
|
T
|
Texwinca Holdings Ltd
HKEX:321
|
HK |
|
Sunyes Electronic Manufacturing Guangdong Holding Co Ltd
SZSE:002388
|
CN |
|
V
|
Viet Nam Ocean Shipping JSC
VN:VOS
|
VN |
Income Statement
Earnings Waterfall
Maat Pharma SA
Maat Pharma SA
Income Statement
Maat Pharma SA
Maat Pharma SA
Currency: EUR
| Dec-2021 | Jun-2022 | Dec-2022 | Jun-2023 | Dec-2023 | Jun-2024 | Dec-2024 | Jun-2025 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||
| Interest Expense |
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
|
| Revenue |
1
N/A
|
1
+11%
|
1
+32%
|
2
+62%
|
2
-4%
|
3
+15%
|
3
+25%
|
4
+22%
|
5
+15%
|
|
| Gross Profit | ||||||||||
| Cost of Revenue |
(0)
|
(0)
|
(0)
|
(1)
|
(1)
|
(1)
|
(1)
|
(2)
|
(1)
|
|
| Gross Profit |
1
N/A
|
1
+5%
|
1
+29%
|
2
+62%
|
2
-6%
|
2
+5%
|
2
+13%
|
2
+23%
|
3
+29%
|
|
| Operating Income | ||||||||||
| Operating Expenses |
(10)
|
(13)
|
(15)
|
(16)
|
(22)
|
(25)
|
(30)
|
(33)
|
(33)
|
|
| Selling, General & Administrative |
(3)
|
(4)
|
(4)
|
(5)
|
(5)
|
(6)
|
(7)
|
(8)
|
(8)
|
|
| Research & Development |
(9)
|
(12)
|
(14)
|
(17)
|
(21)
|
(24)
|
(27)
|
(29)
|
(29)
|
|
| Other Operating Expenses |
2
|
3
|
4
|
5
|
5
|
4
|
4
|
4
|
4
|
|
| Operating Income |
(9)
N/A
|
(12)
-38%
|
(14)
-10%
|
(15)
-9%
|
(20)
-35%
|
(24)
-22%
|
(28)
-16%
|
(30)
-7%
|
(30)
+2%
|
|
| Pre-Tax Income | ||||||||||
| Interest Income Expense |
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(1)
|
(1)
|
(1)
|
(2)
|
|
| Total Other Income |
(0)
|
(0)
|
(0)
|
0
|
1
|
1
|
0
|
0
|
0
|
|
| Pre-Tax Income |
(9)
N/A
|
(12)
-37%
|
(14)
-11%
|
(15)
-7%
|
(20)
-34%
|
(24)
-23%
|
(29)
-19%
|
(31)
-8%
|
(31)
+0%
|
|
| Net Income | ||||||||||
| Income from Continuing Operations |
(9)
|
(12)
|
(14)
|
(15)
|
(20)
|
(24)
|
(29)
|
(31)
|
(31)
|
|
| Net Income (Common) |
(9)
N/A
|
(12)
-37%
|
(14)
-11%
|
(15)
-7%
|
(20)
-34%
|
(24)
-23%
|
(29)
-19%
|
(31)
-8%
|
(31)
+0%
|
|
| EPS (Diluted) |
-0.91
N/A
|
-1.24
-36%
|
-1.39
-12%
|
-1.32
+5%
|
-1.73
-31%
|
-2.02
-17%
|
-2.21
-9%
|
-2.06
+7%
|
-1.95
+5%
|
|
Switch to:
Switch to:
See Also
Discover More
